OncoSec Medical Inc. (OTCMKTS:ONCS) today announced that the company will present at the Bioelectrochemistry Gordon Research Conference to be organized at the University of New England in Biddeford, ME during July 6-11, 2014. The Chief Medical Officer of the Company, Robert Pierce and a member of its Scientific Advisory Board, Richard Heller will represent the company at the conference. The company is currently engaged in the development of DNA-based intratumoral cancer immunotherapy, ImmunoPulse. Dr. Pierce will present a discussion scheduled to start at 12:00 p.m. ET on Tuesday, July 8, 2014, as a part of the session, “Pore-Inducing Methods for Gene Transfer.” Dr. Heller will present a discussion scheduled to start at 08:30 p.m. ET on Thursday, July 10, 2014, as a part of the session, “Electroporation-Mediated Gene Delivery.”
The Bioelectrochemistry Gordon Research Conference will provide a common platform for leading clinicians and researchers to share and discuss about molecular mechanisms related to several aspects of bioelectrochemistry. In addition, the Conference will also facilitate an opportunity to discuss the findings of the newer studies which could potentially expand knowledge frontiers in this field. The Conference will bring together key professionals working in the field to discuss further development of related techniques yield potential clinical applications. The Conference will emphasis the connections between the planned tracks so as to create unique engagement opportunities for participants through unified meeting.
OncoSec Medical Inc. (OTCMKTS:ONCS) is a biopharmaceutical company that leverages its electroporation platform technology to develop ImmunoPulse, a potential immunotherapy targeting solid tumors. Its electroporation platform enhances the local delivery and uptake of DNA-based immune modulating agents. Clinical trials involving ImmunoPulse have demonstrated a preliminary evidence of anti-tumor activity against various skin cancers with an acceptable safety profile. The company is currently undertaking three Phase II studies targeting cutaneous T-cell lymphoma, metastatic melanoma and Merkel cell carcinoma.